Sponsored Content
WuXi has started construction of a state-of-the-art, integrated R&D and manufacturing center at the company's headquarters (see press release). This 250,000 sq. ft. facility will be operational in 2017 and can accommodate 800 scientists. The center will provide comprehensive concept to clinic biologics discovery, development, and GMP manufacturing services on one consolidated campus. This facility utilizes WuXi’s single-source technology platforms.
WuXi Biologics (A wholly owned subsidiary of WuXi AppTec)
info@wuxibiologics.comwww.wuxibiologics.com/news-events/#WXnews